Dipeptidyl peptidase-4 inhibitor (sitagliptin) improves insulin sensitivity and atherosclerosis-related biomarkers in patients with type 2 diabetes

被引：0
|
作者：
Yamane, T. [1 ]
Suzuki, Y. [1 ]
Iwai, R. [2 ]
Sakuma, Y. [2 ]
Yoshida, S. [1 ]
Hashimoto, N. [3 ]
机构：
[1] Asahi Gen Hosp, Chiba, Japan
[2] Asahi Gen Hosp, Clin Lab, Chiba, Japan
[3] Tokyo Womens Med Univ, Chiba, Japan
来源：
DIABETOLOGIA | 2012年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
785
引用
收藏
页码：S323 / S323
页数：1
相关论文
共 50 条
  • [1] The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Vascular Endothelial Function in Type 2 Diabetes
    Kubota, Yoshiaki
    Miyamoto, Masaaki
    Takagi, Gen
    Ikeda, Takeshi
    Kirinoki-Ichikawa, Sonoko
    Tanaka, Kotoko
    Mizuno, Kyoichi
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2012, 27 (11) : 1364 - 1370
  • [2] Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes
    Nomiyama, Takashi
    Akehi, Yuko
    Takenoshita, Hiromasa
    Nagaishi, Ryoko
    Terawaki, Yuichi
    Nagasako, Hisahiro
    Kudo, Tadachika
    Kodera, Takehiko
    Kobayashi, Kunihisa
    Urata, Hidenori
    Yanase, Toshihiko
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2012, 95 (02) : E27 - E28
  • [3] Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
    Mega, Cristina
    Teixeira-Lemos, Edite
    Fernandes, Rosa
    Reis, Flavio
    JOURNAL OF DIABETES RESEARCH, 2017, 2017
  • [4] Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes
    Hanefeld, Markolf
    Herman, Gary A.
    Wu, Mei
    Mickel, Carolyn
    Sanchez, Matilde
    Stein, Peter P.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (06) : 1329 - 1339
  • [5] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
    I. Raz
    M. Hanefeld
    L. Xu
    C. Caria
    D. Williams-Herman
    H. Khatami
    Diabetologia, 2006, 49 : 2564 - 2571
  • [6] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
    Raz, I.
    Hanefeld, M.
    Xu, L.
    Caria, C.
    Williams-Herman, D.
    Khatami, H.
    DIABETOLOGIA, 2006, 49 (11) : 2564 - 2571
  • [7] Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
    Aschner, Pablo
    Kipnes, Mark S.
    Lunceford, Jared K.
    Sanchez, Matilde
    Mickel, Carolyn
    Williams-Herman, Debora E.
    DIABETES CARE, 2006, 29 (12) : 2632 - 2637
  • [8] Effects of the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, on Colorectal Carcinogenesis in a Model of Type 2 Diabetes
    Inoue, Takuya
    Yorifuji, Naoki
    Fujiwara, Kaori
    Sakanaka, Taisuke
    Iguchi, Munetaka
    Narabayashi, Ken
    Okada, Toshihiko
    Nouda, Sadaharu
    Kakimoto, Kazuki
    Ishida, Kumi
    Kawakami, Ken
    Abe, Yosuke
    Takeuchi, Toshihisa
    Umegaki, Eiji
    Higuchi, Kazuhide
    GASTROENTEROLOGY, 2014, 146 (05) : S654 - S655
  • [9] EFFECT OF THE DIPEPTIDYL PEPTIDASE-4 INHIBITOR SITAGLIPTIN IN OLDER ADULTS WITH TYPE 2 DIABETES MELLITUS
    Stafford, Sara
    Elahi, Dariush
    Meneilly, Graydon S.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2011, 59 (06) : 1148 - 1149
  • [10] Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin
    Herman, G. A.
    Stein, P. P.
    Thornberry, N. A.
    Wagner, J. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (05) : 761 - 767
12345